Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00836095 · ClinicalTrials.gov registry record · Phase 4
Comparison of ProSeal Laryngeal Mask Airway to Laryngeal Mask Airway Supreme
A Phase 4 study of Adverse Effect of Unspecified General Anesthetics, sponsored by Milton S. Hershey Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT00836095: Completed Phase 4 study of Adverse Effect of Unspecified General Anesthetics, sponsored by Milton S. Hershey Medical Center.
NCT00836095 is a Phase 4 study of Adverse Effect of Unspecified General Anesthetics that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 52 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00836095, a Phase 4 study of Adverse Effect of Unspecified General Anesthetics, has completed, sponsored by Milton S. Hershey Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
Laryngeal mask airway is a widely used device in routine anesthesia for airway management during surgery. It consists of a tube with an inflatable cuff that is inserted into the mouth after induction of general anesthesia. The Proseal Laryngeal mask airway and the Laryngeal mask airway Supreme are two variants of the Laryngeal mask airway. The laryngeal mask airway Supreme is a newer version of the laryngeal mask airway. The research is being done to compare two variants of the laryngeal mask airway: the Proseal laryngeal mask airway and the Laryngeal mask airway Supreme. This study will determine if the newer model, the Laryngeal mask airway Supreme, is easier to insert and is better positioned than the older model, the Proseal laryngeal mask airway. Both models are approved for use by the FDA, and are routinely used to assure the airway during general anesthesia.
Primary Outcome
The insertion time will be the measured time that it takes the anesthesiologist to insert the airway and verify ventilation of the patient's airway. Data reported will be time in seconds ± the standard deviation.
Conditions Studied
Interventions
- DEVICE Supreme Laryngeal mask airway
- DEVICE Proseal laryngeal mask airway
Study Locations (1)
Pennsylvania
- PennState Hershey Milton S. Hershey Medical Center - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2009-01 |
| Est. Completion | 2013-04 |
| Phase | Phase 4 |
What the finished NCT00836095 record still lists
NCT00836095 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Adverse Effect of Unspecified General Anesthetics appearing as the primary indexed condition, and to 2 interventions - of which Supreme Laryngeal mask airway is the first listed.
NCT00836095 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00836095 about?
NCT00836095 is a clinical study titled "Comparison of ProSeal Laryngeal Mask Airway to Laryngeal Mask Airway Supreme". Laryngeal mask airway is a widely used device in routine anesthesia for airway management during surgery. It consists of a tube with an inflatable cuff that is inserted into the mouth after induction of general anesthesia. The Proseal Laryngeal mask airway and the Laryngeal mask airway Supreme are t...
What is the current status of trial NCT00836095?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2009-01. Estimated completion is 2013-04.
What conditions does trial NCT00836095 study?
This clinical trial studies the following conditions: Adverse Effect of Unspecified General Anesthetics.
What interventions are being tested in trial NCT00836095?
The interventions under investigation include: Supreme Laryngeal mask airway (DEVICE), Proseal laryngeal mask airway (DEVICE).
Who is sponsoring clinical trial NCT00836095?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00836095 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00836095's enrollment target sits among peer trials
52 1233rd of 2000 higher than 753 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia